Viatris’s Sale of its Equity Stake in Biocon Biologics Limited to Biocon
December 06, 2025
On December 6, 2025, Viatris Inc. (“Viatris”), a global healthcare company, announced it has entered into definitive agreements with Biocon Limited (“Biocon”) for the sale of Viatris’s equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon will acquire all of Viatris’s convertible preferred equity in Biocon Biologics Limited for a total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon. Cravath is representing Viatris in connection with the transaction.
The Cravath team is led by partners Mark I. Greene, Aaron M. Gruber and Edward O. Minturn and includes associate Hannah Gehringer on M&A matters; partner George E. Zobitz and associate Emily E. Gust on financing matters; and partner J. Leonard Teti II, of counsel Kiran Sheffrin and associates Carlos Nicholas Obando and Josh Banafsheha on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1993, University of Pennsylvania Law School
-
B.A., 1989, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 2007, Stanford Law SchoolOrder of the Coif
-
M.Phil., 2004, University of CambridgeGates Cambridge Scholar
-
B.S., 2003, Yale Collegesumma cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2016, New York University School of Lawcum laude
-
B.A., 2013, Duke Universitywith Distinction
- New York
Education
Admitted In
-
J.D., 1995, New York University School of Lawwith Honors, cum laude
-
B.A., 1991, Franklin & Marshall College
- New York
Education
Admitted In
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
October 08, 2026
Viatris’s $1.65 Billion Acquisition of Pacira
On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
August 11, 2026
Viatris’s Sale of TYRVAYA to Harrow
On August 6, 2026, Harrow, a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (“Viatris”), a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. Under the terms of the agreement, Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments tied to TYRVAYA's net sales, for a potential total consideration of up to $100 million. Cravath is representing Viatris in connection with the transaction.
